CALGARY, June 2, 2016 /CNW/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce that findings of a study performed by the Baker IDI Heart and Diabetes Institute and Resverlogix has been published in the journal 'Metabolism', titled: "Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial."
Apabetalone Published In 'Metabolism' Journal
Data summarized in the publication was gathered from patients with prediabetes mellitus characterized by abnormal blood glucose levels. Treatment with apabetalone/RVX-208 (200 mg/day) for 29-33 days led to not only a reduction in glucose absorption but also suppression of endogenous glucose production. The significance of these findings are as follows: (1) short duration of RVX-208 treatment had effects on glucose metabolism, and (2) both the reduction in glucose absorption and production are expected to be of benefit in patients with prediabetes mellitus.
Bio International 2016 Presentation
Resverlogix also announces that Mr. Donald McCaffrey, President and Chief Executive Officer is scheduled to present at BIO International 2016, in San Francisco, CA, in which a corporate update will be provided.
Date: Tuesday, June 7, 2016
Time: 11:15 am PDT / 2:15 pm EDT
We invite interested parties to visit: http://www.veracast.com/webcasts/bio/internationalconvention2016/37214271955.cfm at the presentation time noted above to listen to the live webcast.
A replay will be available one hour after the live presentation and may be accessed via the same link above. The archived webcast will be available until September 5, 2016.
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL).
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.
Follow us on Twitter: @Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on our blog at http://www.resverlogix.com/blog
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the potential role of apabetalone in the treatment of CVD, DM, chronic kidney disease, Alzheimer's disease, Orphan diseases, and peripheral artery disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Resverlogix Corp.
For further information: Investor Relations, Email: email@example.com, Phone: 403-254-9252